Annual EBITDA
-$26.73 M
+$13.59 M+33.70%
31 December 2023
Summary:
Achieve Life Sciences annual earnings before interest, taxes, depreciation & amortization is currently -$26.73 million, with the most recent change of +$13.59 million (+33.70%) on 31 December 2023. During the last 3 years, it has fallen by -$12.26 million (-84.69%). ACHV annual EBITDA is now -1373.05% below its all-time high of $2.10 million, reached on 31 December 1996.ACHV EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$12.09 M
-$4.49 M-59.07%
30 September 2024
Summary:
Achieve Life Sciences quarterly earnings before interest, taxes, depreciation & amortization is currently -$12.09 million, with the most recent change of -$4.49 million (-59.07%) on 30 September 2024. Over the past year, it has dropped by -$5.82 million (-92.84%). ACHV quarterly EBITDA is now -192.83% below its all-time high of $13.02 million, reached on 31 December 2016.ACHV Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$29.95 M
-$5.82 M-24.12%
30 September 2024
Summary:
Achieve Life Sciences TTM earnings before interest, taxes, depreciation & amortization is currently -$29.95 million, with the most recent change of -$5.82 million (-24.12%) on 30 September 2024. Over the past year, it has increased by +$2.78 million (+8.49%). ACHV TTM EBITDA is now -388.96% below its all-time high of $10.36 million, reached on 30 September 2017.ACHV TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ACHV EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +33.7% | -92.8% | +8.5% |
| 3 y3 years | -84.7% | -82.3% | +1.7% |
| 5 y5 years | -113.3% | -230.8% | -78.5% |
ACHV EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -84.7% | +33.7% | -161.0% | +3.6% | -24.8% | +27.9% |
| 5 y | 5 years | -113.3% | +33.7% | -323.7% | +3.6% | -131.2% | +27.9% |
| alltime | all time | -1373.0% | +33.7% | -192.8% | +3.6% | -389.0% | +27.9% |
Achieve Life Sciences EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$12.09 M(+59.1%) | -$29.95 M(+24.1%) |
| June 2024 | - | -$7.60 M(+35.1%) | -$24.13 M(+0.5%) |
| Mar 2024 | - | -$5.62 M(+21.4%) | -$24.00 M(-10.2%) |
| Dec 2023 | -$26.73 M(-33.7%) | -$4.63 M(-26.1%) | -$26.73 M(-18.3%) |
| Sept 2023 | - | -$6.27 M(-16.1%) | -$32.72 M(-16.1%) |
| June 2023 | - | -$7.47 M(-10.6%) | -$38.99 M(-6.1%) |
| Mar 2023 | - | -$8.36 M(-21.3%) | -$41.53 M(+3.0%) |
| Dec 2022 | -$40.33 M(+22.6%) | -$10.62 M(-15.3%) | -$40.33 M(+9.6%) |
| Sept 2022 | - | -$12.54 M(+25.3%) | -$36.79 M(+19.1%) |
| June 2022 | - | -$10.01 M(+39.9%) | -$30.88 M(-3.9%) |
| Mar 2022 | - | -$7.16 M(+0.9%) | -$32.12 M(-2.4%) |
| Dec 2021 | -$32.90 M(+127.3%) | -$7.09 M(+6.9%) | -$32.90 M(+8.1%) |
| Sept 2021 | - | -$6.63 M(-41.1%) | -$30.45 M(+10.7%) |
| June 2021 | - | -$11.25 M(+41.8%) | -$27.51 M(+43.9%) |
| Mar 2021 | - | -$7.93 M(+71.1%) | -$19.11 M(+32.0%) |
| Dec 2020 | -$14.47 M(-11.1%) | -$4.64 M(+25.7%) | -$14.47 M(+11.5%) |
| Sept 2020 | - | -$3.69 M(+29.3%) | -$12.98 M(+0.3%) |
| June 2020 | - | -$2.85 M(-13.4%) | -$12.95 M(-5.4%) |
| Mar 2020 | - | -$3.30 M(+4.7%) | -$13.70 M(-15.8%) |
| Dec 2019 | -$16.27 M(+29.9%) | -$3.15 M(-13.9%) | -$16.27 M(-3.0%) |
| Sept 2019 | - | -$3.65 M(+1.6%) | -$16.77 M(+2.6%) |
| June 2019 | - | -$3.60 M(-38.8%) | -$16.35 M(+5.6%) |
| Mar 2019 | - | -$5.88 M(+61.1%) | -$15.48 M(+23.5%) |
| Dec 2018 | -$12.53 M(+97.3%) | -$3.65 M(+13.0%) | -$12.53 M(-0.3%) |
| Sept 2018 | - | -$3.23 M(+18.3%) | -$12.57 M(+8.0%) |
| June 2018 | - | -$2.73 M(-6.8%) | -$11.64 M(+29.2%) |
| Mar 2018 | - | -$2.93 M(-20.7%) | -$9.01 M(+41.9%) |
| Dec 2017 | -$6.35 M(+325.9%) | -$3.69 M(+60.8%) | -$6.35 M(-161.3%) |
| Sept 2017 | - | -$2.29 M(+2195.0%) | $10.36 M(+46.8%) |
| June 2017 | - | -$100.00 K(-62.3%) | $7.06 M(+222.4%) |
| Mar 2017 | - | -$265.00 K(-102.0%) | $2.19 M(-246.8%) |
| Dec 2016 | -$1.49 M(-91.9%) | $13.02 M(-332.5%) | -$1.49 M(-91.7%) |
| Sept 2016 | - | -$5.60 M(+12.7%) | -$17.93 M(+5.7%) |
| June 2016 | - | -$4.97 M(+25.9%) | -$16.95 M(-3.1%) |
| Mar 2016 | - | -$3.94 M(+15.6%) | -$17.50 M(-5.4%) |
| Dec 2015 | -$18.51 M(-37.3%) | -$3.41 M(-26.3%) | -$18.51 M(-15.8%) |
| Sept 2015 | - | -$4.63 M(-16.1%) | -$21.97 M(-10.4%) |
| June 2015 | - | -$5.52 M(+11.4%) | -$24.53 M(-7.7%) |
| Mar 2015 | - | -$4.95 M(-28.0%) | -$26.59 M(-9.9%) |
| Dec 2014 | -$29.51 M(-15.9%) | -$6.87 M(-4.4%) | -$29.51 M(-0.3%) |
| Sept 2014 | - | -$7.19 M(-5.1%) | -$29.61 M(-10.2%) |
| June 2014 | - | -$7.58 M(-3.8%) | -$32.97 M(-5.1%) |
| Mar 2014 | - | -$7.87 M(+12.9%) | -$34.74 M(-1.0%) |
| Dec 2013 | -$35.10 M(+27.4%) | -$6.97 M(-33.9%) | -$35.10 M(-2.5%) |
| Sept 2013 | - | -$10.55 M(+13.0%) | -$36.01 M(+6.8%) |
| June 2013 | - | -$9.34 M(+13.4%) | -$33.72 M(+11.3%) |
| Mar 2013 | - | -$8.23 M(+4.5%) | -$30.30 M(+10.0%) |
| Dec 2012 | -$27.54 M(+24.0%) | -$7.88 M(-4.6%) | -$27.54 M(-0.3%) |
| Sept 2012 | - | -$8.26 M(+39.6%) | -$27.62 M(+17.9%) |
| June 2012 | - | -$5.92 M(+8.0%) | -$23.43 M(+4.2%) |
| Mar 2012 | - | -$5.48 M(-31.0%) | -$22.49 M(+1.3%) |
| Dec 2011 | -$22.21 M(+108.5%) | -$7.95 M(+95.0%) | -$22.21 M(+37.4%) |
| Sept 2011 | - | -$4.08 M(-18.0%) | -$16.16 M(+7.9%) |
| June 2011 | - | -$4.97 M(-4.4%) | -$14.98 M(+16.6%) |
| Mar 2011 | - | -$5.21 M(+173.7%) | -$12.84 M(+20.5%) |
| Dec 2010 | -$10.65 M(-850.9%) | -$1.90 M(-34.3%) | -$10.65 M(-766.4%) |
| Sept 2010 | - | -$2.90 M(+2.0%) | $1.60 M(-24.3%) |
| June 2010 | - | -$2.84 M(-5.9%) | $2.11 M(+464.4%) |
| Mar 2010 | - | -$3.02 M(-129.2%) | $374.00 K(-59.6%) |
| Dec 2009 | $1.42 M | $10.35 M(-534.2%) | $925.00 K(-106.3%) |
| Sept 2009 | - | -$2.38 M(-47.9%) | -$14.63 M(-1.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2009 | - | -$4.58 M(+85.5%) | -$14.91 M(+6.8%) |
| Mar 2009 | - | -$2.47 M(-52.6%) | -$13.97 M(-10.0%) |
| Dec 2008 | -$11.02 M(-24.4%) | -$5.21 M(+95.6%) | -$15.53 M(+80.7%) |
| Sept 2008 | - | -$2.66 M(-26.7%) | -$8.59 M(-27.2%) |
| June 2008 | - | -$3.63 M(-9.8%) | -$11.80 M(-19.7%) |
| Mar 2008 | - | -$4.03 M(-333.0%) | -$14.69 M(+1.1%) |
| Dec 2007 | -$14.58 M(-43.2%) | $1.73 M(-129.4%) | -$14.53 M(-38.9%) |
| Sept 2007 | - | -$5.87 M(-10.0%) | -$23.79 M(-4.5%) |
| June 2007 | - | -$6.52 M(+68.8%) | -$24.90 M(+4.4%) |
| Mar 2007 | - | -$3.86 M(-48.7%) | -$23.85 M(-7.1%) |
| Dec 2006 | -$25.68 M(+21.0%) | -$7.54 M(+7.9%) | -$25.68 M(+18.1%) |
| Sept 2006 | - | -$6.98 M(+27.6%) | -$21.75 M(-8.1%) |
| June 2006 | - | -$5.47 M(-3.8%) | -$23.68 M(+6.5%) |
| Mar 2006 | - | -$5.69 M(+57.6%) | -$22.23 M(+4.7%) |
| Dec 2005 | -$21.22 M(+32.1%) | -$3.61 M(-59.5%) | -$21.22 M(-7.4%) |
| Sept 2005 | - | -$8.91 M(+121.4%) | -$22.91 M(+30.5%) |
| June 2005 | - | -$4.02 M(-14.1%) | -$17.55 M(+1.9%) |
| Mar 2005 | - | -$4.68 M(-11.5%) | -$17.23 M(+7.3%) |
| Dec 2004 | -$16.06 M(+56.6%) | -$5.29 M(+49.1%) | -$16.06 M(+20.6%) |
| Sept 2004 | - | -$3.55 M(-4.1%) | -$13.32 M(+9.0%) |
| June 2004 | - | -$3.70 M(+5.3%) | -$12.22 M(+5.9%) |
| Mar 2004 | - | -$3.51 M(+37.7%) | -$11.54 M(+12.5%) |
| Dec 2003 | -$10.26 M(-11.5%) | -$2.55 M(+4.1%) | -$10.26 M(+0.8%) |
| Sept 2003 | - | -$2.45 M(-18.8%) | -$10.18 M(-6.9%) |
| June 2003 | - | -$3.02 M(+35.2%) | -$10.94 M(-4.6%) |
| Mar 2003 | - | -$2.23 M(-9.7%) | -$11.46 M(-1.1%) |
| Dec 2002 | -$11.59 M(-2543.8%) | -$2.47 M(-23.0%) | -$11.59 M(+2.7%) |
| Sept 2002 | - | -$3.21 M(-9.4%) | -$11.29 M(+278.9%) |
| June 2002 | - | -$3.55 M(+50.1%) | -$2.98 M(+150.2%) |
| Mar 2002 | - | -$2.36 M(+8.9%) | -$1.19 M(-351.0%) |
| Dec 2001 | $474.40 K(-106.9%) | -$2.17 M(-142.6%) | $474.50 K(-82.1%) |
| Sept 2001 | - | $5.10 M(-390.1%) | $2.65 M(-156.6%) |
| June 2001 | - | -$1.76 M(+152.2%) | -$4.69 M(-9.9%) |
| Mar 2001 | - | -$697.00 K(-7360.4%) | -$5.21 M(-24.2%) |
| Dec 2000 | -$6.88 M(-1266.3%) | $9600.00(-100.4%) | -$6.88 M(-23.0%) |
| Sept 2000 | - | -$2.25 M(-1.2%) | -$8.92 M(-2626.6%) |
| June 2000 | - | -$2.27 M(-3.8%) | $353.20 K(-229.7%) |
| Mar 2000 | - | -$2.36 M(+15.9%) | -$272.40 K(-134.4%) |
| Dec 1999 | $589.50 K(-105.3%) | -$2.04 M(-129.0%) | $791.50 K(+429.8%) |
| Sept 1999 | - | $7.03 M(-342.4%) | $149.40 K(-101.7%) |
| June 1999 | - | -$2.90 M(+123.1%) | -$8.88 M(-2.2%) |
| Mar 1999 | - | -$1.30 M(-51.5%) | -$9.08 M(-18.8%) |
| Dec 1998 | -$11.08 M(-1683.0%) | -$2.68 M(+34.1%) | -$11.18 M(+34.7%) |
| Sept 1998 | - | -$2.00 M(-35.5%) | -$8.30 M(+10.7%) |
| June 1998 | - | -$3.10 M(-8.8%) | -$7.50 M(+82.9%) |
| Mar 1998 | - | -$3.40 M(-1800.0%) | -$4.10 M(-685.7%) |
| Dec 1997 | $700.00 K(-66.7%) | $200.00 K(-116.7%) | $700.00 K(-78.1%) |
| Sept 1997 | - | -$1.20 M(-500.0%) | $3.20 M(-57.3%) |
| June 1997 | - | $300.00 K(-78.6%) | $7.50 M(-8.5%) |
| Mar 1997 | - | $1.40 M(-48.1%) | $8.20 M(+272.7%) |
| Dec 1996 | $2.10 M(-145.7%) | $2.70 M(-12.9%) | $2.20 M(-161.1%) |
| Sept 1996 | - | $3.10 M(+210.0%) | -$3.60 M(-56.1%) |
| June 1996 | - | $1.00 M(-121.7%) | -$8.20 M(+12.3%) |
| Mar 1996 | - | -$4.60 M(+48.4%) | -$7.30 M(+711.1%) |
| Dec 1995 | -$4.60 M(-41.8%) | -$3.10 M(+106.7%) | -$900.00 K(-86.2%) |
| Sept 1995 | - | -$1.50 M(-178.9%) | -$6.50 M(+44.4%) |
| June 1995 | - | $1.90 M(+5.6%) | -$4.50 M(-28.6%) |
| Mar 1995 | - | $1.80 M(-120.7%) | -$6.30 M(-21.3%) |
| Dec 1994 | -$7.90 M | -$8.70 M(-1840.0%) | -$8.00 M(-1242.9%) |
| Sept 1994 | - | $500.00 K(+400.0%) | $700.00 K(+250.0%) |
| June 1994 | - | $100.00 K(0.0%) | $200.00 K(+100.0%) |
| Mar 1994 | - | $100.00 K | $100.00 K |
FAQ
- What is Achieve Life Sciences annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Achieve Life Sciences?
- What is Achieve Life Sciences annual EBITDA year-on-year change?
- What is Achieve Life Sciences quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Achieve Life Sciences?
- What is Achieve Life Sciences quarterly EBITDA year-on-year change?
- What is Achieve Life Sciences TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Achieve Life Sciences?
- What is Achieve Life Sciences TTM EBITDA year-on-year change?
What is Achieve Life Sciences annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of ACHV is -$26.73 M
What is the all time high annual EBITDA for Achieve Life Sciences?
Achieve Life Sciences all-time high annual earnings before interest, taxes, depreciation & amortization is $2.10 M
What is Achieve Life Sciences annual EBITDA year-on-year change?
Over the past year, ACHV annual earnings before interest, taxes, depreciation & amortization has changed by +$13.59 M (+33.70%)
What is Achieve Life Sciences quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of ACHV is -$12.09 M
What is the all time high quarterly EBITDA for Achieve Life Sciences?
Achieve Life Sciences all-time high quarterly earnings before interest, taxes, depreciation & amortization is $13.02 M
What is Achieve Life Sciences quarterly EBITDA year-on-year change?
Over the past year, ACHV quarterly earnings before interest, taxes, depreciation & amortization has changed by -$5.82 M (-92.84%)
What is Achieve Life Sciences TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of ACHV is -$29.95 M
What is the all time high TTM EBITDA for Achieve Life Sciences?
Achieve Life Sciences all-time high TTM earnings before interest, taxes, depreciation & amortization is $10.36 M
What is Achieve Life Sciences TTM EBITDA year-on-year change?
Over the past year, ACHV TTM earnings before interest, taxes, depreciation & amortization has changed by +$2.78 M (+8.49%)